LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
LAVA Therapeutics N.V. - Ordinary Shares (LVTX)
Company Research
Source: GlobeNewswire
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1LAVA-1266 on track for Q2 2024 IND submissionStrong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2024. “LAVA continues to advance our pipeline of Gammabody programs and is excited to initiate the combination arm of pembrolizumab with LAVA-1207 this quarter. We look forward to sharing an update on the LAVA-1207 program during the second ha
Show less
Read more
Impact Snapshot
Event Time:
LVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LVTX alerts
High impacting LAVA Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
LVTX
News
- LAVA Therapeutics (NASDAQ: LVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference [Yahoo! Finance]Yahoo! Finance
- LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceGlobeNewswire
- LAVA Announces Annual Meeting of ShareholdersGlobeNewswire
- LAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswire
LVTX
Earnings
- 11/16/23 - Beat
LVTX
Analyst Actions
- 6/28/24 - HC Wainwright
LVTX
Sec Filings
- 6/20/24 - Form 6-K
- 6/6/24 - Form 6-K
- 5/21/24 - Form 6-K
- LVTX's page on the SEC website